ALT — Altimmune, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326190 ·
Last close
$3.11
Market Cap
$604.95M
52W High
$3.40
52W Low
$2.57
ADV30
4,628,178
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -24,244,000 | -22,563,000 | 335,630,000 | 97,601,000 | 51,643,000 |
| Dec 2025 | 26,000 | — | -28,893,000 | -27,358,000 | 279,929,000 | 43,760,000 | 55,037,000 |
| Sep 2025 | 5,000 | — | -20,859,000 | -19,014,000 | 218,447,000 | 61,236,000 | 32,846,000 |
| Jun 2025 | 5,000 | — | -22,922,000 | -22,146,000 | 190,350,000 | 183,105,000 | 28,983,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-71,637,000
Investing CF
$-131,062,000
Financing CF
$251,196,000
CapEx
$-22,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-672,046,000
Inventory
—
Receivables
$1,665,000
ST Investments
$233,939,000
EBIT TTM
$-88,378,000
Pretax Income TTM
$-91,081,000
Interest Exp TTM
$2,703,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$31,000
EBITDA
$-98,634,000
Free Cash Flow
$-48,786,124
Enterprise Value
$314,689,056
Total Cash
$326,280,992
Total Debt
$36,020,000
Shares Out
194,517,701
Trailing EPS
$-0.76
Book Value
$2.44
ROE
-28.9%
ROA
-17.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 41,000 | -94,489,000 | -88,093,000 | 279,929,000 | 55,037,000 | — | -67,535,000 |
| Dec 2024 | 20,000 | -103,172,000 | -95,059,000 | 139,306,000 | 15,798,000 | — | -79,848,000 |
| Dec 2023 | 426,000 | -83,510,000 | -88,447,000 | 210,640,000 | 16,541,000 | — | -75,810,000 |
| Dec 2022 | -68,000 | -87,740,000 | -84,713,000 | 206,928,000 | 21,635,000 | — | -62,586,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$371,000
NetIncome TTM
$-90,548,000
OpCashFlow TTM
$0
Assets (Latest)
$139,306,000
Forward EPS
$-0.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | $602.46M | $4.80 | — |
| ARVN | ARVINAS, INC. | $610.71M | $9.34 | — |
| VSTM | Verastem, Inc. | $621.27M | $6.86 | — |
| SGMT | Sagimet Biosciences Inc. | $628.85M | $10.21 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $630.33M | $16.97 | — |
News headlines (Yahoo Finance, 1h cache)
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...
2026-08-12 23:03 · Yahoo
Altimmune Q2 Earnings Call Highlights
2026-08-12 14:05 · Yahoo
Altimmune, Inc. Q2 2026 Earnings Call Summary
2026-08-12 12:30 · Yahoo
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
2026-08-12 11:30 · Yahoo
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff
2026-07-28 18:42 · Yahoo
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
2026-07-28 14:04 · Yahoo
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%
2026-07-28 12:33 · Yahoo
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
2026-07-29 11:00 · Yahoo
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
2026-08-19 14:55 · Yahoo
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
2026-08-19 14:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.